The groundbreaking rise of Viagra has firmly established as a benchmark of pharmaceutical success, yet its future within the broader market now triggers questions about potential returns . Alternative versions are undercutting patent protection , prompting anxieties that supporting companies heavily reliant to Viagra's once-dominant influence could